CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 150 enrolled
Drug / intervention
Calcifediol +2 moredrug
Likely dose
Calcifediol 400mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02962102
NCT02962102Phase 2Completed
CompareCT.gov

Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury (ACTIVATE-AKI)

David Leaf·interventional·Posted Nov 11, 2016·Updated Sep 29, 2025

In Brief

A Phase 2 clinical trial evaluating Calcifediol, Calcitriol, and 1 other intervention for Critically Ill and Acute Kidney Injury. Completed, enrolled 150 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the efficacy of calcifediol (25-hydroxyvitamin D) and calcitriol (1,25-dihydroxyvitamin D) in preventing and reducing the severity of acute kidney injury (AKI) in critically ill patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCritically Ill, Acute Kidney Injury
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 11, 2016
Enrollment StartApr 3, 2017
Primary CompletionJul 16, 2020
Study CompletionAug 6, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.6 years ago

Interventions

Calcifedioldrug

Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4

Calcitrioldrug

Calcitriol 4mcg orally daily x 5

Placebosdrug

Placebo (medium chain triglyceride oil) orally daily x 5